The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone

Table 5

Univariate and multivariate logistic regression analysis to evaluate the factors which contribute to body weight reduction for over 5%.

Variables	Odds ratio (95% CI) univariate	P	Odds ratio (95% CI) multivariate	P
Age (per year)	1.02 (0.97–1.07)	0.54
Male	1.32 (0.33–5.28)	0.69
Body weight (per 1.0 kg)	1.01 (0.98–1.05)	0.49
BMI (per 1.0 kg/m^2)	1.06 (0.96–1.17)	0.23
Hypertension	1.41 (0.44–4.51)	0.56
Dyslipidemia	1.12 (0.31–3.97)	0.86
Smoking	1.91 (0.59–6.10)	0.28
Liraglutide	8.13 (2.24–29.5)	<0.01	9.04 (1.12–73.1)	0.04
Sitagliptin	0.17 (0.03–0.80)	<0.01	1.19 (0.12–12.0)	0.88
Pioglitazone	0.46 (0.09–2.27)	0.34
Metformin	2.66 (0.08–9.30)	0.96
Sulfonylurea	3.17 (0.90–11.1)	0.07	1.61 (0.28–9.43)	0.60
Albumin (per 1.0 mg/dL)	0.13 (0.01–1.13)	0.06	0.11 (0.01–2.42)	0.16
AST (per 10 IU/L)	1.22 (0.97–1.61)	0.09	1.03 (0.95–1.11)	0.47
ALT (per 10 IU/L)	1.05 (0.88–1.25)	0.54
γ-GTP (per 10 IU/L)	1.05 (0.94–1.15)	0.33
Fast blood glucose (per 10 mg/dL)	1.13 (1.03–1.26)	<0.01	1.14 (1.01–1.28)	0.04
HbA1c (per 1.0%)	1.32 (0.85–2.02)	0.21
LDL-cholesterol (per 10 mg/dL)	0.87 (0.71–1.06)	0.16
Triglyceride (per 10 mg/dL)	1.02 (0.98–1.06)	0.41
Platelet counts (per ×10^4/𝜇L)	0.91 (0.82–1.02)	0.09	0.98 (0.72–1.33)	0.42
APRI index (per 1.0)	3.22 (0.01–997)	0.04	2.11 (0.01–332)	0.77

CI: confidence interval; BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyl transpeptidase; HbA1c: hemoglobin A1c; APRI: AST-to-platelet counts ratio index.